Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY (MRK)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Merck and : NOXXON announces its participation in two french investor conferences in October 2017

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/02/2017 | 10:18am CET

Release date- 29092017 - Berlin, Germany - NOXXON Pharma N.V. (EuroNext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced that it would participate in two conferences focused on institutional investors in October in Paris.

NOXXON will present at the French Financial Analysts Society / Societe Francaise des Analystes Financiers (SFAF) on October 3, 2017 at 10:00am at 135 boulevard Haussmann, 75008 Paris in the 'Salle Hausmann'.

NOXXON will also participate in the CF&B Large & Midcap Event which will take place on the 4th and 5th of October 2017 at the Palais Brongiart, 28 Place de la Bourse, 75002 Paris. NOXXON pharma will be available for meetings with institutional investors.

Contact:

Tel: +49 (0) 30 726 247 0

Email: [email protected]

About NOXXON

NOXXON Pharma N.V. is a clinical-stage biopharmaceutical company focused on cancer treatment. NOXXON's goal is to significantly enhance the effectiveness of cancer treatments including immunooncology approaches (such as immune checkpoint inhibitors) and current standards of care (such as chemotherapy and radiotherapy).

NOXXON's Spiegelmer platform has generated a proprietary pipeline of clinical-stage product candidates including its lead cancer drug candidate NOX-A12 (olaptesed pegol), which is the subject of a clinical immuno-oncology collaboration agreement with Merck & Co. / MSD (NYSE: MRK) to study NOX-A12 combined with Merck & Co.'s anti-PD-1 checkpoint-inhibiting antibody Keytruda (pembrolizumab) in pancreatic and colorectal cancer. The clinical trial testing NOX-A12 as monotherapy and in combination with Keytruda is being conducted at one of the leading centers for cancer research and treatment, the National Center for Tumor Diseases in Heidelberg, Germany. NOXXON is supported by a strong group of leading international investors, including TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, DEWB, NGN and Seventure. NOXXON has its statutory seat in Amsterdam, the Netherlands and its office in Berlin, Germany.

Disclaimer

Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial indicators, developments of the financial situation or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for updating such information, which only represents the state of affairs on the day of publication.

(c) 2017 Electronic News Publishing -, source ENP Newswire

Valeurs citées dans l'article
ChangeLast1st jan.
NOXXON PHARMA NV -3.77% 5.1 Real-time Quote.-24.09%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK AND COMPANY
02/20MERCK AND : Groundbreaking lung cancer approval a big boost for AZs Imfinzi
AQ
02/19MERCK AND : - Selumetinib Granted Orphan Drug Designation by the U.S. FDA for Ne..
AQ
02/19AstraZeneca's immunotherapy drug wins key lung cancer approval
RE
02/19BERGENBIO : completes recruitment into first stage of Phase II breast cancer tri..
AQ
02/19BERGENBIO : completes recruitment into first stage of Phase II breast cancer tri..
AQ
02/17MERCK AND : `Really Durable Benefit` Emerging With Bladder Cancer ImmunoTx
AQ
02/17Merck/Pfizers cancer immunotherapy latecomer hits a snag
AQ
02/16MERCK AND : Pharma Group MSD (Merck) Announces Plans For New Biotech Facility In..
AQ
02/15BERGENBIO ASA : - Results for the Fourth Quarter and Full Year 2017
AQ
02/15MERCK AND : Announces Discontinuation of APECS Study Evaluating Verubecestat for..
AQ
More news
News from SeekingAlpha
02/20BIOTECHS : Still Well Placed For More Gains 
02/20Biotech Forum Daily Digest For February 20th 
02/20COMPUGEN LTD. : An Undervalued Disruptive Innovation Company 
02/20WALL STREET BREAKFAST : Albertsons Scoops Up Rest Of Rite Aid 
02/20AGENUS : Positioned To Rapidly Enhance Shareholder Value 
Financials ($)
Sales 2018 41 616 M
EBIT 2018 13 718 M
Net income 2018 8 465 M
Debt 2018 13 842 M
Yield 2018 3,41%
P/E ratio 2018 17,33
P/E ratio 2019 13,94
EV / Sales 2018 4,02x
EV / Sales 2019 3,86x
Capitalization 153 B
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 66,7 $
Spread / Average Target 18%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Clark Golestani Chief Information Officer & Executive VP
Roy D. Baynes Chief Medical Officer
Thomas Henry Glocer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY-0.50%153 359
JOHNSON & JOHNSON-7.19%357 710
NOVARTIS-3.37%224 785
PFIZER-2.84%216 135
ROCHE HOLDING LTD.-9.37%207 160
AMGEN3.23%133 241